Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia

Ubiquilin 2 pathology in ALS and ALS/dementia A study of a five-generation family with the usually fatal disorder amyotrophic lateral sclerosis (ALS) has identified mutations in the UBQLN2 gene, which encodes the ubiquitin-like protein ubiquilin 2, as a cause of ALS and ALS/dementia. This finding is...

Full description

Saved in:
Bibliographic Details
Published inNature (London) Vol. 477; no. 7363; pp. 211 - 215
Main Authors Deng, Han-Xiang, Chen, Wenjie, Hong, Seong-Tshool, Boycott, Kym M., Gorrie, George H., Siddique, Nailah, Yang, Yi, Fecto, Faisal, Shi, Yong, Zhai, Hong, Jiang, Hujun, Hirano, Makito, Rampersaud, Evadnie, Jansen, Gerard H., Donkervoort, Sandra, Bigio, Eileen H., Brooks, Benjamin R., Ajroud, Kaouther, Sufit, Robert L., Haines, Jonathan L., Mugnaini, Enrico, Pericak-Vance, Margaret A., Siddique, Teepu
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 08.09.2011
Nature Publishing Group
Subjects
Online AccessGet full text
ISSN0028-0836
1476-4687
1476-4687
DOI10.1038/nature10353

Cover

More Information
Summary:Ubiquilin 2 pathology in ALS and ALS/dementia A study of a five-generation family with the usually fatal disorder amyotrophic lateral sclerosis (ALS) has identified mutations in the UBQLN2 gene, which encodes the ubiquitin-like protein ubiquilin 2, as a cause of ALS and ALS/dementia. This finding is of particular interest as it links familial and sporadic forms of the disease through a ubiquilin 2 pathology observed in the spinal cords of ALS cases and in the brains of ALS/dementia cases with or without UBQLN2 mutations. This novel pathology shows that abnormalities in ubiquilin 2 are associated with defects in the protein degradation pathway, abnormal protein aggregation and neurodegeneration, indicating a common pathogenic mechanism that might be a target for therapeutic intervention. Amyotrophic lateral sclerosis (ALS) is a paralytic and usually fatal disorder caused by motor-neuron degeneration in the brain and spinal cord. Most cases of ALS are sporadic but about 5–10% are familial. Mutations in superoxide dismutase 1 ( SOD1 ) 1 , 2 , TAR DNA-binding protein ( TARDBP , also known as TDP43 ) 3 , 4 and fused in sarcoma ( FUS , also known as translocated in liposarcoma ( TLS )) 5 , 6 account for approximately 30% of classic familial ALS. Mutations in several other genes have also been reported as rare causes of ALS or ALS-like syndromes 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 . The causes of the remaining cases of familial ALS and of the vast majority of sporadic ALS are unknown. Despite extensive studies of previously identified ALS-causing genes, the pathogenic mechanism underlying motor-neuron degeneration in ALS remains largely obscure. Dementia, usually of the frontotemporal lobar type, may occur in some ALS cases. It is unclear whether ALS and dementia share common aetiology and pathogenesis in ALS/dementia. Here we show that mutations in UBQLN2 , which encodes the ubiquitin-like protein ubiquilin 2, cause dominantly inherited, chromosome-X-linked ALS and ALS/dementia. We describe novel ubiquilin 2 pathology in the spinal cords of ALS cases and in the brains of ALS/dementia cases with or without UBQLN2 mutations. Ubiquilin 2 is a member of the ubiquilin family, which regulates the degradation of ubiquitinated proteins. Functional analysis showed that mutations in UBQLN2 lead to an impairment of protein degradation. Therefore, our findings link abnormalities in ubiquilin 2 to defects in the protein degradation pathway, abnormal protein aggregation and neurodegeneration, indicating a common pathogenic mechanism that can be exploited for therapeutic intervention.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
Present address: Laboratory of Genetics and Department of Microbiology, Chonbuk National University Medical School, Chonbuk, South Korea.
These authors contributed equally to this work.
Present address: National Natural Science Foundation of China, Beijing, China.
Present address: Department of Neurology, Sakai Hospital Kinki University Faculty of Medicine, Osaka, Japan.
Present address: Institute of Neurological Sciences, Glasgow, UK.
ISSN:0028-0836
1476-4687
1476-4687
DOI:10.1038/nature10353